Vico Therapeutics, a Leiden, The Netherlands-based clinical-stage genetic medicines company developing therapies for severe neurological diseases, raised $60M in Series B funding.
The round was led by Ackermans & van Haaren along with Droia Ventures, EQT Life Sciences and Kurma Partners with participation from Polaris Partners, Pureos Bioventures and Eurazeo. The company also announced that Jeroen Vangindertael, Ph.D., investment manager at AvH, will join Vico’s board of directors.
The company intends to use the funds to support its ongoing Phase 1/2a clinical trial evaluating VO659 in patients with spinocerebellar ataxia type 3 and type 1 and Huntington’s disease.
Led by CEO Micah Mackison, Vico Therapeutics is a clinical-stage genetic medicines company developing antisense oligonucleotide (ASO) RNA modulating therapies for patients with severe neurological diseases. Its lead product candidate, VO659, is currently in Phase 1/2a clinical development for the treatment of spinocerebellar ataxia types 3 and 1 and Huntington’s disease and is the only ASO in the clinic that targets the underlying CAG repeat expansions that cause all nine known polyglutamine diseases. Vico’s research platform designs fit-for-purpose ASOs by applying precision chemistry with mechanisms of action ideally suited to target genetic neurological diseases.
The company also announced that Jeroen Vangindertael, Ph.D., investment manager at AvH, will join Vico’s board of directors.
FinSMEs
05/01/2024